3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
39
Nivolumab
13
Cisplatin
12
Paclitaxel
11
Docetaxel
11
Carboplatin
10
atezolizumab
9
Trastuzumab
9
Gemcitabine
9
Cyclophosphamide
8
fludarabine
7
Bevacizumab
7
aldesleukin
6
durvalumab
5
Taxes
5
Oxaliplatin
5
Magnetic Resonance Spectroscopy
5
Leucovorin
5
Irinotecan
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
avelumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Ipilimumab
4
Drug Therapy
4
Cetuximab
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
tislelizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Thoracic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled